PO-091: TPExtreme randomized trial: Docetaxel-Platinum(P)-Cetuximab(C) versus 5FU-P-C in recurrent/metastatic HNSCC. (February 2015) - Guigay, J.; Keilholz, U.; Mesia, R.; Vintonenko, N.; Bourhis, J.; Auperin, A.